These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39153249)

  • 1. Real-life Data on First- and Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer With Abiraterone, Enzalutamide and Cabazitaxel - A multicentric Study From Portugal.
    Botelho F; Braga I; Leão R; Teves F; Dias J; Rodrigues F; Oliveira J; Augusto I; Portela C; Febra J; Custódio S; Liu P; Gago P; Miranda A; Silva C; Pacheco-Figueiredo L
    Clin Genitourin Cancer; 2024 Dec; 22(6):102169. PubMed ID: 39153249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.
    Tanaka N; Izumi K; Nakai Y; Shima T; Kato Y; Mita K; Kamiyama M; Inoue S; Hoshi S; Okamura T; Yoshio Y; Enokida H; Chikazawa I; Kawai N; Hashimoto K; Fukagai T; Shigehara K; Takahara S; Mizokami A
    Prostate; 2025 Jan; 85(1):21-29. PubMed ID: 39301921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication Prescription Policy for US Veterans With Metastatic Castration-Resistant Prostate Cancer: Causal Machine Learning Approach.
    Gopukumar D; Menon N; Schoen MW
    JMIR Med Inform; 2024 Nov; 12():e59480. PubMed ID: 39561358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.
    Yanagisawa T; Fukuokaya W; Hatakeyama S; Narita S; Muramoto K; Katsumi K; Takahashi H; Urabe F; Mori K; Tashiro K; Iwatani K; Shimomura T; Habuchi T; Kimura T
    Prostate; 2025 Feb; 85(2):165-174. PubMed ID: 39417629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The PROSPECT Study.
    Liontos M; Bournakis E; Bournakis A; Kostouros E; Zolota V; Papatheodoridi AP; Karalis K; Kyriazoglou A; Zakopoulou R; Vasili E; Tzovaras A; Dimitriadis I; Emmanouil G; Mauri D; Christodoulou C; Tsiatas M; Zagouri F; Bamias A
    Clin Genitourin Cancer; 2024 Dec; 22(6):102170. PubMed ID: 39191062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Sachdeva A; Jones C; Hoyle A; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Gilson C; Rush H; Abdel-Aty H; Amos CL; Murphy C; Chowdhury S; Malik Z; Russell JM; Parkar N; Pugh C; Diaz-Montana C; Pezaro C; Grant W; Saxby H; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzouebi M; Parikh O; Robinson A; Montazeri AH; Wylie J; Zarkar A; Cathomas R; Brown MD; Jain Y; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.
    Patrikidou A; Saieva C; Lee-Ying R; Nuzzo PV; Zarif TE; McClure H; Davidsohn M; Eid M; Spinelli GP; Catalano F; Cremante M; Fotia G; Rossetti S; Valenca L; Vauchier C; Ottanelli C; Andrade L; Gennusa V; Mestre RP; Fornarini G; Pignata S; Procopio G; Santini D; Ravi P; Sweeney C; Heng D; De Giorgi U; Fizazi K; Russo A; Francini E;
    Clin Genitourin Cancer; 2024 Dec; 22(6):102230. PubMed ID: 39461026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Androgens as Predictive Biomarkers: Results From a Randomized Clinical Trial Comparing Enzalutamide and Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer.
    Ternov KK; Fode M; Sønksen J; Bisbjerg R; Lindberg H; Palapattu G; Bratt O; Østergren PB
    Clin Genitourin Cancer; 2024 Dec; 22(6):102200. PubMed ID: 39244832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Ai J; Jian L; Wen X; Huo X; Yang X; Jiang J; Zhang T
    Clin Transl Oncol; 2024 Oct; 26(10):2559-2571. PubMed ID: 38750344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Bossi A; Foulon S; Maldonado X; Sargos P; MacDermott R; Kelly P; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Salem N; Calabro F; Berdah JF; Hasbini A; Silva M; Boustani J; Ribault H; Fizazi K;
    Lancet; 2024 Nov; 404(10467):2065-2076. PubMed ID: 39580202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [
    Muniz M; Sartor O; Orme JJ; Koch RM; Rosenow HR; Mahmoud AM; Andrews JR; Kase AM; Riaz IB; Belge Bilgin G; Thorpe MP; Kendi AT; Johnson GB; Ravi P; Kwon ED; Childs DS
    J Nucl Med; 2024 Dec; 65(12):1932-1938. PubMed ID: 39477495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.
    Agarwal N; Azad AA; Carles J; Fay AP; Matsubara N; Heinrich D; Szczylik C; De Giorgi U; Joung JY; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Lin X; Healy CG; Di Santo N; Zohren F; Fizazi K
    Future Oncol; 2024; 20(29):2123-2135. PubMed ID: 38995237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database.
    Eule CJ; Kuna EM; Robin TP; Gershman B; Flaig TW; Kim SP
    Urol Oncol; 2024 Dec; 42(12):447.e17-447.e24. PubMed ID: 39191549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
    Saad F; Armstrong AJ; Oya M; Vianna K; Özgüroğlu M; Gedye C; Buchschacher GL; Lee JY; Emmenegger U; Navratil J; Virizuela JA; Salazar A; Maillet D; Uemura H; Kim J; Oscroft E; Barker L; Degboe A; Clarke NW
    Eur Urol Oncol; 2024 Dec; 7(6):1394-1402. PubMed ID: 38582650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Desai KB; Serritella AV; Stadler WM; O'Donnell PH; Sweis RF; Szmulewitz RZ
    Clin Cancer Res; 2024 Jun; 30(11):2384-2392. PubMed ID: 38536082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.